Oscar Health, Inc. (OSCR) 股票分析

公司概述

Oscar Health, Inc. operates as a healthcare technology company within the United States, providing health plans to a diverse range of customers including individuals, families, employees, and small group markets while also powering others throughout the healthcare system via its platform solutions. The company is situated in the Healthcare sector and specifically functions within the Healthcare Plans industry, a position that places it at the intersection of insurance regulation and technological innovation. Its current market capitalization stands at $4.36B, supported by annual revenue of $11.70B and a workforce comprising 2305 employees. These financial figures indicate that Oscar Health has established a significant operational footprint, generating substantial top-line volume while maintaining a valuation that reflects both its revenue scale and the high-risk profile inherent in the healthcare technology space.

财务健康

The company reported revenue of $11.70B over the trailing twelve months, yet recorded a net income of $-443,151,008 and an EBITDA of $-367,464,992, revealing a cost structure where operational expenses significantly exceed pre-tax earnings despite high revenue generation. Despite the negative net income and EBITDA, the company maintains a free cash flow of $698.00M, which provides a critical layer of financial flexibility allowing for potential operational scaling or strategic investments without immediate reliance on external equity financing. Profitability analysis shows a gross margin of 14.4%, an operating margin of -11.9%, and a profit margin of -3.8%, indicating that while the core business generates value from services rendered, broader operating costs and strategic investments currently suppress overall profitability. On the liability side, the company holds $3.99B in cash against $498.80M in debt, resulting in a debt-to-equity ratio of 50.86, suggesting a balance sheet that is leveraged yet possesses a substantial cash buffer to service obligations. Liquidity is assessed via a current ratio of 0.95, which indicates that current assets barely cover current liabilities, signaling a need for efficient working capital management in the short term. Return metrics include a Return on Equity of -44.4% and a Return on Assets of -4.4%, revealing that management has not yet achieved positive capital efficiency, likely due to the heavy investment phase required to grow the healthcare technology platform.

估值评估

Valuation metrics present a complex picture with a trailing P/E ratio of N/A and a forward P/E of 10.88, the disparity implying that while current earnings are negative, the market anticipates a potential earnings turnaround or normalization in the future trajectory. The price-to-book ratio stands at 4.45, indicating that the market values the company at a significant premium over its book value, which often reflects intangible assets and future growth potential in the healthcare technology sector. Alternative valuation measures include a price-to-sales ratio of 0.37 and an EV/EBITDA of -2.36, suggesting that investors are pricing the stock primarily on revenue generation rather than current earnings power. Price action shows a 52-week high of $23.80 and a 52-week low of $10.69, with the current market price trading at a position that reflects recent volatility within this established range. The stock exhibits a beta of 1.93, meaning its price volatility is nearly double that of the broader market, highlighting the high risk and potential for amplified price swings relative to general market movements.

Growth & Income

Revenue growth stands at 17.3% year-over-year, whereas earnings growth is N/A due to the reported net loss, indicating that top-line expansion is currently outpacing the ability to generate bottom-line profit. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the company reinvests all available earnings into growth initiatives rather than returning capital to shareholders. This non-dividend strategy is typical for growth-stage healthcare technology firms that prioritize platform development and market share acquisition over immediate income distribution. Overall, the growth and income profile is characterized by aggressive revenue expansion funded by significant cash reserves, with no current reliance on dividend income for shareholder returns.